Two recent case reports demonstrate promising results for the use of BioTissue’s cryopreserved amniotic membrane (CAM) devices in managing complex ocular surface disease (OSD).
Presented at this week’s 2026 Southern Council of Optometrists (SECO) meeting, both poster findings detailed situations involving patients with persistent corneal surface disease—where conventional therapies did not provide relief—focusing on epithelial recovery, symptom reduction, and visual acuity following CAM placement.
First, a look at Biotissue.
As a developer of human amniotic membrane tissue-derived products, the biotechnology company has created a portfolio of CAM-based technologies credited with treating over 900K patients since its inception in 1997.
Included among these products:
Tell me about Prokera.
As we’ve mentioned in prior coverage of this FDA-cleared therapeutic device, the self-retained Prokera Slim is a sutureless graft that utilizes CAM to provide quick symptom relief and reduce OSD-associated inflammation—rehabilitating corneal tissue while maintaining comfort.
- See here for how it works (delivery via a self-containing conformer ring)
- And click here for a more detailed description
The average treatment time is anywhere from 3 to 5 days (and may include a second treatment based on the condition's severity).
And what do we know about this associated case study?
Successful Management of Recurrent Corneal Erosion with Cryopreserved Amniotic Membrane in a Post-LASIK Patient with Occupational Exacerbation was presented by Seema Nanda, OD, of the Nanda Dry Eye & Vision Institute in Houston, Texas.
The situation: A 27-year-old female LASIK patient presented with RCE and persistent tearing, photophobia, blurred vision, and redness that impacted her daily work activities.
- Initial management: Included lubrication, bandage contact lens, and topical medications
- The result: Limited relief (including 8 RCE episodes over a 5-month period)
- Enter in: Prokera Slim.
- The result: Visual acuity (VA) improvements, a significant reduction in corneal staining and symptoms, and the patient’s return to regular work function.
- After 19 months: The patient's symptoms came back but were managed with another CAM placement—leading to a complete resolution of corneal staining and symptoms for a further 18 months.
- The result: Visual acuity (VA) improvements, a significant reduction in corneal staining and symptoms, and the patient’s return to regular work function.
Can I get a closer look at the exam findings and treatment outcomes?
See here for those details, from initial presentation to post-treatment (at post-device placement, 3-month follow-up, 19-month recurrence, and later post-retreatment).
So what’s the takeaway?
Based on Dr. Nanda’s presentation, this case highlighted the efficacy of amniotic membrane therapy (via the Prokera Slim) in managing refractory RCE and restoring occupational function.
Got it. Now for the device in this second case study.
That would be the CAM360 AmnioGraft, introduced to the U.S. commercial market in June 2024.
What it is: As a ringless CAM, this device is marketed as the only hydrated CAM that provides anti-inflammatory, -scarring, and -angiogenic properties for ocular use.
It’s also shelf-stable (requiring no refrigeration) due to the use of BioTissue’s proprietary SteriTrek technology, a unique preservation process that protects the tissue’s bioactive components while also maintaining its natural hydration.
- See here for a rundown on its adhesive properties and efficacy.
Noted. And the patient case?
Treatment of Stage 1 NK Secondary to Acoustic Neuroma Removal with Cryopreserved Amniotic Membrane was presented by Katherine Rachon, OD, FAAO, Dipl ABO, of Virginia Eye Consultants.
The case: Involved a 77-year-old patient with stage 1 neurotrophic keratitis (NK) and reduced corneal sensitivity with the following history:
- Removal of an acoustic neuroma of the right vestibular nerve
- Removal of neoplasm of the right eyelid
- Prior to cataract surgery
And what did the patient present with?
Clinical examination of the right eye revealed upper lid lagophthalmos, 3+ inferior superficial punctate keratitis (SPK), reduced corneal sensitivity, and 20/25 best-corrected visual acuity (BCVA).
The patient also demonstrated fluctuating blurry vision—temporarily improved with artificial use—but denied dryness, tearing, irritation, or grittiness.
- For a closer look at her ocular history, see slide 6 of the presentation.
Where does the CAM360 come in?
The device—with a dissolvable collagen shield—was placed for 72 hours with eyelid closure support (specifically: tape).
… and what was the outcome?
During a follow-up examination, improvements were noted from 3+ to trace SPK—which was “consistent with improved corneal epithelial integrity.”
The patient denied any ocular pain or irritation.
And what if I want more insights from these scenarios?
If you’re attending SECO, you're in luck!
- Dr. Nanda’s poster will be available in the Exhibit Hall during Session #2 on Friday (Feb. 27) from 12 p.m. to 2 p.m.
- Dr. Rachon’s poster will be available in the Exhibit Hall during session #4 on Saturday (Feb. 28) from 9:45 am to 11:45 am.
Now for the big picture on these scenarios.
As BioTissue President and CEO Ted Davis noted:
“These case reports reflect a broader shift toward regenerative therapies in ocular surface care, particularly for patients with persistent epithelial disease that does not fully respond to conventional approaches.”